Quadrant Capital Group’s ImmunityBio IBRX Stock Holding History

Quadrant Capital Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-145	Closed	-$1K	–	2584
2021 Q4	$1K	Buy	+145	New	+$1.09K	﹤0.01%	2316

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Quadrant Capital Group's IBRX Position: Q1 2022 in Review

Quadrant Capital Group sold out of ImmunityBio (IBRX) in Q1 2022, closing a stake of 145 shares — an estimated $1K sold.

Quadrant Capital Group first reported a position in IBRX in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 149 funds tracked by Wall St. Rank hold IBRX as of Q1 2022.

Quadrant Capital Group reported no remaining ImmunityBio position as of Q1 2022 after selling out during the quarter.
Quadrant Capital Group sold 145 ImmunityBio shares in Q1 2022, an estimated $1K.
Quadrant Capital Group first reported a position in ImmunityBio in Q4 2021 and held it in 1 quarter.
Quadrant Capital Group's ImmunityBio position peaked at $1K in Q4 2021.
149 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2022.

Based on Quadrant Capital Group's 13F filing for Q1 2022, filed 6 May 2022.